drugset / Trial / NCT00778388
Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers
RandomizedParallel-groupDouble-blindPrevention
Summary
The objective is to confirm the optimal dose of IC43 in regard to immunogenicity, safety and tolerability.
Timeline
- Start
- 2008-09
- Primary completion
- 2009-09
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | IC43 | Vaccine | 50 ug | Intramuscular |
| Comparator | IC43 | Vaccine | 100 ug | Intramuscular |
| Comparator | IC43 | Vaccine | 200 ug | Intramuscular |
Indications
No indication recorded.